Enovis Corporation (NYSE:ENOV – Get Free Report) Director Sharon Wienbar acquired 900 shares of the business’s stock in a transaction on Wednesday, November 11th. The stock was purchased at an average cost of $27.76 per share, with a total value of $24,984.00. Following the acquisition, the director directly owned 45,551 shares of the company’s stock, valued at $1,264,495.76. This represents a 2.02% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
Enovis Price Performance
Shares of Enovis stock traded up $0.10 during trading hours on Friday, reaching $27.74. The stock had a trading volume of 1,205,392 shares, compared to its average volume of 1,879,055. The stock’s 50 day moving average is $20.52 and its 200 day moving average is $23.22. The firm has a market capitalization of $1.60 billion, a PE ratio of -3.01 and a beta of 1.31. Enovis Corporation has a twelve month low of $16.70 and a twelve month high of $31.67. The company has a current ratio of 2.15, a quick ratio of 1.08 and a debt-to-equity ratio of 0.82.
Enovis (NYSE:ENOV – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.11. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The business had revenue of $558.73 million for the quarter, compared to analyst estimates of $557.12 million. During the same period in the prior year, the company posted $0.75 EPS. The company’s revenue for the quarter was up 1.8% on a year-over-year basis. Equities analysts expect that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.
Key Headlines Impacting Enovis
- Positive Sentiment: Directors Angela S. Lalor and Sharon Wienbar bought a combined 3,531 shares in transactions on November 10 and 11, investing about $100,000. Insider buying can signal confidence, though the purchases are relatively small compared with the company’s overall market value. Lalor SEC filing Wienbar SEC filing
- Neutral Sentiment: Enovis management will present at the Jefferies Global Healthcare Conference on November 17. The announcement may give investors an opportunity to hear updates, but it included no new guidance or business developments. Conference announcement
Hedge Funds Weigh In On Enovis
A number of hedge funds have recently made changes to their positions in ENOV. IFP Advisors Inc raised its holdings in shares of Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after acquiring an additional 1,174 shares during the last quarter. Allworth Financial LP acquired a new stake in shares of Enovis in the second quarter worth approximately $36,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Enovis in the second quarter worth approximately $39,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Enovis during the second quarter worth approximately $48,000. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of Enovis during the third quarter worth approximately $55,000. Institutional investors and hedge funds own 98.45% of the company’s stock.
Wall Street Analyst Weigh In
ENOV has been the topic of a number of recent analyst reports. BTIG Research increased their price target on Enovis from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. BMO Capital Markets set a $27.00 price objective on Enovis in a research report on Tuesday, September 1st. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Finally, Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $38.62.
View Our Latest Analysis on Enovis
Enovis Company Profile
Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.
Featured Articles
- Five stocks we like better than Enovis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
